Inspire® Upper Airway Stimulation (UAS) System German Post-Market Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2017-01-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to obtain additional safety and efficacy data on the use of Inspire® therapy for the treatment of subjects with moderate to severe Obstructive Sleep Apnea.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Inspire® Upper Airway Stimulation System

NCT02675816

Obstructive Sleep Apnea

TERMINATED PHASE4

Inspire® Post-Approval Study / Protocol Number 2014-001

NCT02413970

Obstructive Sleep Apnea

ACTIVE_NOT_RECRUITING NA

Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry

NCT02907398

Obstructive Sleep Apnea

ACTIVE_NOT_RECRUITING

Effect of Upper Airway Stimulation in Patients With Obstructive Sleep Apnea

NCT03760328

Obstructive Sleep Apnea

COMPLETED NA

Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)

NCT01161420

Obstructive Sleep Apnea

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center, prospective, single-arm study conducted under a common implant and follow-up protocol. Each subject will serve as their own control.

The study will collect pre-operative two-night home sleep testing, medical history and subject quality of life measures. Intra- and post- operative procedure data will be collected. Therapy usage and device adjustment data, as well as a subject satisfaction with therapy survey, will be collected for additional analysis.

Post-implant, procedure- and device-related events, QoL questionnaires, therapy usage and device adjustment data will be collected. Sleep study data will collected during the 2-month visit and, if conducted, a 3-month visit using a single night in-lab titration PSGs At 6 and 12 months post-implant, 2-night home sleep testing will be completed. Safety data will be collected throughout the study. Subjects will be exited from the study following the 12-month visits.

The subject population will consist of otherwise healthy men and women that are at least 21 years old and have: 1) Provided written informed consent to participate, 2) Indicated a willingness to comply with study requirements for the specified follow-up duration, 3) Met all inclusion and exclusion criteria of this protocol.

Up to 60 subjects will be implanted at up to 5 sites in Germany.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obstructive Sleep Apnea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Inspire Upper Airway Stimulation System

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Inspire® UAS System

This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System.

Group Type OTHER

Inspire® Upper Airway Stimulation (UAS) System

Intervention Type DEVICE

This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System is a permanent, implantable therapy device, which consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the patient receives a remove to activate the therapy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Inspire® Upper Airway Stimulation (UAS) System

This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System is a permanent, implantable therapy device, which consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the patient receives a remove to activate the therapy.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Inspire® Therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Likely suffer moderate-to-severe OSA based on history and physical, or have an established diagnosis of OSA (≥ 15 AHI\<65) based on a prior sleep test
2. Willing and capable to have stimulation hardware permanently implanted, and to use the patient programmer to activate the stimulation
3. Willing and capable to return for all follow-up visits and conduct sleep studies at home, including the evaluation procedures and filling out questionnaires
4. Willing and capable of providing informed consent

Exclusion Criteria

Contraindications

1. Any anatomical finding that would compromise the performance of upper airway stimulation, such as the presence of complete concentric collapse of the soft palate
2. Have any condition or procedure that has compromised neurological control of the upper airway
3. Unable or do not have the necessary assistance to operate the patient programmer
4. Pregnant or plan to become pregnant
5. Require magnetic resonance imaging (MRI)
6. Have an implantable device that may be susceptible to unintended interaction with the Inspire system.

Additional exclusions for study purposes only:
7. Body Mass Index (BMI) of \> 35
8. Central + mixed apneas \> 25% of the total apnea-hypopnea index (AHI)
9. Any chronic medical illness or condition that contraindicates a surgical procedure under general anesthesia, as judged by the clinical study Investigator
10. Has a terminal illness with life expectancy \< 12 months
11. Active psychiatric disease (psychotic illness, major depression, or acute anxiety attacks) which prevents subject compliance with the requirements of the investigational study testing
12. Any other reason the investigator deems subject is unfit for participation in the study

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes